Role of 99mTc-octreotide acetate scintigraphy in suspected lung cancer compared with 18F-FDG dual-head coincidence imaging

Journal of Nuclear Medicine

Volumn 48, Issue 9, 2007, Pages 1442-1448

  Wang, Feng ^a   Wang, Zizheng ^a   Yao, Weixuan ^a   Xie, Hong ^a   Xu, Jie ^a   Tian, Li ^b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING CHEST HOSPITAL   (China)

Author keywords

18F FDG; Dual head coincidence imaging; Lung cancer; Scintigraphy; Somatostatin receptor scintigraphy

Indexed keywords

FLUORODEOXYGLUCOSE F 18; OCTREOTIDE; OCTREOTIDE TC 99M; TECHNETIUM 99M; 99MTC OCTREOTIDE; 99MTC-OCTREOTIDE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHADENOPATHY; MALE; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; COMPARATIVE STUDY; LUNG TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OCTREOTIDE; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS;

EID: 34548572926     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.040824     Document Type: Article

References (37)

1. Jemal A, Thomas A, Murray T, et al. Cancer statistics: 2002. CA Cancer J Clin. 2002;52:23-47.
2. Xiong J-F, Zhou H-B, Chi H-S, et al. Epidemic trend study of malignant tumors incidence from 1999 to 2004 in Shenzhen. Chin J Cancer Prev Treat. 2006;13:572-576.
3. Yang L, Li L, Chen Y, et al. Mortality time trends and the incidence and mortality estimation and projection for lung cancer in China. Chin J Lung Cancer. 2005;8:274-278.
4. Zhang S-W, Chen W-Q, Kong L-Z, et al. An analysis of cancer incidence and mortality from 30 cancer registries in China, 1998-2002. Bull Chin Cancer. 2005;15:430-448.
5. Lee C, Kang KH, Koh Y, et al. Characteristics of lung cancer in Korea, 1997. Lung Cancer. 2000;30:15-22.
6. Deslauriers J, Gregoire J. Clinical and surgical staging of non-small cell lung cancer. Chest. 2000;117(4 suppl 1):96S-103S.
7. Webb WR, Gatsouris S, Zerhouni EA, et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiology Diagnostic Oncology Group. Radiology. 1992;182:319-323.
8. Gupta NC, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med. 1996;37:943-948.
9. Dewan NA, Shehan CJ, Reeb SD, Gobar LS, Scott WJ, Ryschon K. Likelihood of malignancy in a solitary pulmonary nodule. Chest. 1997;112:416-422.
10. Herder GJ, Golding RP, Gobar L, et al. The performance of 18-F-fluoro-deoxyglucose positron emission tomography in small solitary pulmonary nodules. Eur J Nucl Med Mol Imaging. 2004;31:1231-1236.
11. Lowe VJ, Fletcher JW, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol. 1998;16:1075-1084.
12. Van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected nonsmall-cell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002;359:1388-1392.
13. Pieterman RM, van Putten JWG, Meuzelaar JJ, et al. Preoperative staging of non-small cell lung cancer with positron emission tomography. N Eng J Med. 2000;343:254-261.
14. Port JL, Kent MS, Korst RJ, et al. Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. Ann Thorac Surg. 2004;77:254-259.
15. Akhurst T, Downey RJ, Ginsberg MS, et al. An initial experience with FDG PET in the imaging of residual disease after induction therapy for lung cancer. Ann Thorac Surg. 2002;73:259-266.
16. Choi NC, Fischman AJ, Niemierko A, et al. Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;54:1024-1035.
17. Kwekkeboom DJ, Kho GS, Lamberts SW, et al. The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med. 1994;221:1106-1113.
18. O'Byrne KJ, Carney D. Somatostatin and the lung. Lung Cancer. 1993;10:151-172.
19. Blum J, Handmaker H, Rinne N, et al. The utility of a somatostatin-type receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules. Chest. 1999;115:224-232.
20. 99mTc depreotide in the evaluation of solitary pulmonary nodules. Chest. 2000;117:1232-1237.
21. Erasmus JJ, McAdams HP, Connolly JE. Solitary pulmonary nodules. Part II. Evaluation of the indeterminate nodule. Radiographics. 2000;20:59-66.
22. Salathe M, Soler M, Bolliger CT, et al. Transbronchial needle aspiration in routine fiberoptic bronchoscopy. Respiration. 1992;59:5-8.
23. Schenk DA, Bower JH, Bryan CL, et al. Transbronchial needle aspiration staging of bronchogenic carcinoma. Am Rev Respir Dis. 1986;134:146-148.
24. Kazerooni EA, Lim FT, Mikhail A, et al. Risk of pneumothorax in CT-guided transthoracic needle aspiration biopsy of the lung. Radiology. 1996;198:371-375.
25. Reubi JC. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med. 1995;36:1825-1835.
26. Virgolini I, Pangerl T, Bischof C, et al. Somatostatin receptor expression in human tissues: a prediction for diagnosis and treatment of cancer. Eur J Nucl Med. 1993;20:716-731.
27. Legovini P, Demis E, Billeci D, et al. 111Indium-pentetrotide pituitary scintigraphy and hormonal responses to octretide in acromegalic patients. J Endocrinol Invest. 1997;20:424-428.
28. De Kerviler E, Cardiot G, Lebtahi R, et al. Somatostatin receptor in forty eight patients with the Zollinger-Ellison syndrome. Eur J Nucl Med. 1994;21:1191-1197.
29. Reubi JC, Laissue J, Krenning EP, Lamberts SWJ. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical application. J Steroid Biochem Mol Biol. 1992;43:27-35.
30. O'Byrne KJ, Carney DN. Somatostatin and the lung. Lung Cancer. 1993;10:151-172.
31. 99mTc- P829. Cancer Res. 1998;58:1850-1859.
32. Grewal RK, Dadparvar S, Yu JQ, et al. Efficacy of Tc-99m depreotide scintigraphy in the evaluation of solitary pulmonary nodules. Cancer J. 2002;8:400-404.
33. 99mTc depreotide compared with F-18 fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected non-small cell lung cancer. Chest. 2004;125:494-501.
34. Shreve PD, Anzai Y. Wahl RL. Pitfalls in oncologic diagnosis with FDG-PET imaging: physiologic and benign variants. Radiographics. 1999;19:61-67.
35. Dwamena BA, Sonnad SS, Angobaldo JO, et al. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s - meta-analytic comparison of PET and CT. Radiology. 1999;213:530-536.
36. Baum RP, Hellwig D, Mezzetti M. Position of nuclear medicine modalities in the diagnostic workup of cancer patients: lung cancer. Q J Nucl Med Mol Imaging. 2004;48:119-142.
37. MacManus MP, Hicks RJ, Matthews JP, et al. High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys. 2001;50:287-293.